[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335556-105":59,"doc-detail-335556-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","comparison-of-differences-in-immune-cells-and-immune-microenvironment-among-different-kinds-of-oncolytic-virus-treatments","Comparison of Differences in Immune Cells and Immune Microenvironment Among Different Kinds of Oncolytic Virus Treatments","","Oncolytic viruses, either naturally occurring or engineered, activate immune responses while selectively replicating in and destroying cancer cells without harming healthy tissues. This review summarizes the properties of oncolytic viruses and compares immune cells and the tumor microenvironment across diverse oncolytic virus therapies. It also details immunological mechanisms underlying oncolytic virus treatment, highlighting how these insights may enable identification of novel and more effective therapeutic targets for cancer management.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparison-of-differences-in-immune-cells-and-immune-microenvironment-among-different-kinds-of-oncolytic-virus-treatments/335556/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparison-of-differences-in-immune-cells-and-immune-microenvironment-among-different-kinds-of-oncolytic-virus-treatments/335556.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are oncolytic viruses and why are they considered promising for cancer therapy?","Question",{"text":113,"@type":114},"Oncolytic viruses can selectively replicate in cancer cells, trigger immunogenic tumor cell death, and activate antitumor immunity while generally sparing healthy tissues. The review frames OVT as an emerging treatment approach that addresses limitations of existing therapies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do oncolytic viruses influence the tumor microenvironment (TME) and immune cells?",{"text":118,"@type":114},"The review explains that oncolytic virus lysis releases tumor antigens that are processed by antigen-presenting cells, leading to T-cell responses against infected and uninfected tumor cells. Viruses and virus-stimulated signals can also promote phagocytosis and broader immune elimination of remaining tumor cells.",{"name":120,"@type":111,"acceptedAnswer":121},"What immune-suppressive factors limit the effectiveness of immunotherapies in many patients?",{"text":122,"@type":114},"The text lists immune system suppression, cytokine-type deficiencies, reduced activity of tumor-infiltrating lymphocytes, impaired antigen-presenting cell function, and weakened effector T-cell activity as major barriers. These factors help explain why only a subset of patients benefits from immunotherapies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335556,1790062955,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","TYPE Review  \nPUBLISHED 11 November 2024 DOI 10.3389/fimmu.2024.1494887  \nOPEN ACCESS  \nEDITED BY  \nPeng Qu,  \nNational Institutes of Health (NIH), United States  \nREVIEWED BY  \nXuesi Hua,  \nUniversity of Michigan, United States Fang Mei,  \nPeking University, China  \n*CORRESPONDENCE  \nShaokuan Fang  \n[jluneu@163.com](jluneu@163.com)  \nRECEIVED 11 September 2024  \nACCEPTED 24 October 2024  \nPUBLISHED 11 November 2024  \nCITATION  \nWu X and Fang S (2024) Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments.  \nFront. Immunol. 15:1494887 .  \ndoi: 10.3389/fimmu.2024.1494887  \nCOPYRIGHT  \n© 2024 Wu and Fang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nComparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments  \nXiaoke Wu and Shaokuan Fang*  \nDepartment of Neurology, Neuroscience Centre, The First Hospital of Jilin University, Changchun, China  \nOncolytic viruses are either naturally occurring or genetically engineered viruses that can activate immune cells and selectively replicate in and destroy cancer cells without damaging healthy tissues. Oncolytic virus therapy (OVT) represents an emerging treatment approach for cancer. In this review, we outline the properties of oncolytic viruses and then offer an overview of the immune cells and tumor microenvironment (TME) across various OVTs. A thorough understanding of the immunological mechanisms involved in OVTs could lead to the identiﬁcation of novel and more effective therapeutic targets for cancer treatment.  \nKEYWORDS  \noncolytic virus, tumor, treatment, immune cell, tumor microenvironment  \n1 Introduction  \nTreatment options for tumors have expanded signiﬁcantly in recent years, driven by an enhanced understanding of the immunologic mechanisms underlying these diseases (1, 2) . These options now include traditional surgical treatments and chemoradiotherapy, as well as innovative approaches like immune checkpoint inhibitors, chimeric antigen receptor Tcells, adoptive cell immunotherapy, monoclonal antibodies, nanoantibodies, and other forms of immunotherapy (3–7) . While surgical resection remains the most effective treatment for cancer and can substantially relieve symptoms, it is often not viable for patients in advanced stages of the disease. Moreover, surgery often leads to distant metastasis and local recurrence post-operatively (8) . Chemoradiotherapy can decelerate cancer growth and prolong survival, however, it poses severe risks due to its damaging effects on normal cells while targeting cancer cells (9, 10) . Immunotherapies, despite their potential, beneﬁt only a select group of patients due to various immunosuppressive factors such as immune system suppression, deﬁciencies in cytokine types, reduced activity of tumor-inﬁltrating lymphocytes, impaired function of antigen-presenting cells, and  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nweakened effector T-cell activity (11–13) . Oncolytic viruses have emerged as one of the most promising treatments to address these challenges (14) . These viruses are capable of selectively replicating within tumor cells, delivering multiple eukaryotic transgene payloads, inducing immunogenic cell death, enhancing antitumor immunity, and exhibiting a safety proﬁle that generally does not overlap with other cancer treatments (15, 16) . Recent clinical trials of oncolytic virus therapy (OVT) have shown minimal severe adverse reactions, with only local injection site reactions and lowgra","cbCaioBPKsFRJHjM","https://ap.wps.com/l/cbCaioBPKsFRJHjM","pdf",1790033,13,"English","# Introduction\n## Overview of cancer treatment options and limitations\n## Rationale for oncolytic virus therapy (OVT)\n# Properties and immune interactions of oncolytic viruses\n## Selective infection and tumor-targeting strategies\n## Antigen release, immune cell activation, and cytokine-driven responses\n## Induced cell death pathways and implications for antitumor immunity","[{\"question\":\"What are oncolytic viruses and why are they considered promising for cancer therapy?\",\"answer\":\"Oncolytic viruses can selectively replicate in cancer cells, trigger immunogenic tumor cell death, and activate antitumor immunity while generally sparing healthy tissues. The review frames OVT as an emerging treatment approach that addresses limitations of existing therapies.\"},{\"question\":\"How do oncolytic viruses influence the tumor microenvironment (TME) and immune cells?\",\"answer\":\"The review explains that oncolytic virus lysis releases tumor antigens that are processed by antigen-presenting cells, leading to T-cell responses against infected and uninfected tumor cells. Viruses and virus-stimulated signals can also promote phagocytosis and broader immune elimination of remaining tumor cells.\"},{\"question\":\"What immune-suppressive factors limit the effectiveness of immunotherapies in many patients?\",\"answer\":\"The text lists immune system suppression, cytokine-type deficiencies, reduced activity of tumor-infiltrating lymphocytes, impaired antigen-presenting cell function, and weakened effector T-cell activity as major barriers. These factors help explain why only a subset of patients benefits from immunotherapies.\"}]","Comparison of Differences in Immune Cells and Immune Microenvironment Among Different Kinds of Oncolytic Virus Treatments | PDF",1790011430,33]